anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An expandable helical stent is provided, wherein the stent may be formed of an amorphous metal alloy or other non-amorphous metal with a securement. The stent is formed from flat or tubular metal in a helical coiled structure which has an undulating pattern. The main stent component may be formed of a single helically coiled component. Alternatively, a plurality of helically coiled ribbons may be used to form a stent heterogeneous in design, material, or other characteristic particular to that stent. The helical tubular structure may be secured with a securement, such as a weld, interlock or a polymer, to maintain the helical coils in a tubular configuration. The helical coils of the main stent component may be spaced apart or nestled to each other-maintain the tubular shape of the helically coiled stent and prevent the polymer layer from sagging at any point between cycles of the coils.
1. Technical Result Preserving the structural integrity of liposomes in liposome preparations.         2. Essence A preparation comprising trehalose and lipid liposomes a biologically-active principle has been encapsulated which is highly insoluble in water and stable over time. The trehalose/lipid liposomes weight ratio is ≤ 1,5, and all of the trehalose was added to the outside of the liposomes already formed before lyophilization.          3. Field of Application Medicine, therapy.
The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel sesquiterpene-lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.
INTRODUCTION: The risk of surgery and postoperative complications increases greatly in frail older patients with sarcopenia. The purpose of this study is to explore the correlation between myostatin (MSTN) levels and cognitive function and postoperative pulmonary complications (PPCs) in older patients undergoing thoracoscopic lobectomy and to determine whether MSTN could be used to predict the risk of postoperative complications and cognitive impairment.
METHODS: A prospective observational study was conducted at the First Affiliated Hospital of Bengbu Medical College, China, between January 2023 and June 2023. The risk factors of PPCs and postoperative cognitive impairment were studied using backward stepwise logistic regression analysis. The independent factors were formed into a linear regression equation to construct a risk score model for each patient. The 122 patients who participated in the study were divided into two groups, a low-level group and a high-level group, based on an MSTN level cut-off; the preoperative MSTN cut-off values was 25.55 ng/mL for cognitive dysfunction and 22.29 ng/mL for PPCs. The PPCs and cognitive function of the groups were compared.
RESULTS: Preoperative MSTN was confirmed as a risk factor for postoperative cognitive dysfunction and PPCs. After surgery, the proportion of patients with cognitive impairment in the high-level group was significantly higher than in the low-level group (P < 0.001). In the high-level group, the incidence of respiratory tract infections was 17.9% higher (P = 0.021), hypoxaemia was 20.5% higher (P = 0.001) and respiratory failure was 14.4% higher (P = 0.012) than in the low-level group. In addition, a high level of MSTN increased the length of hospital stay (P < 0.001) and decreased the Barthel Index score (P < 0.001).
CONCLUSIONS: The study findings suggest that MSTN could be used as an index to predict complications and cognitive impairment after thoracoscopic lobectomy in older patients with sarcopenia and to provide evidence for reducing postoperative cognitive impairment and PPCs.
The Intervention will be the standard therapy sessions. Participants will receive a standard smoking cessation treatment based on the most recent clinical practice guideline from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence19. The investigative team has considerable expertise in developing and evaluating behavioral and pharmacological treatments for smoking cessation. Treatment will be delivered in eight, 90-minute sessions over an eight-week period.
We report a 30-case series from the Pain Management Center at the Massachusetts General Hospital where we have applied a guideline to convert chronic treatment for pain from full agonist opioids (FAO) to buprenorphine (BUP). Of the patients, 24 (80 percent) elected to continue BUP over FAO. Five conversions were stopped for side effects (fatigue) and/or lack of sufficient pain reduction. One patient elected not to participate on the day that the conversion was to begin. There were no major adverse events. We conclude that conversion to BUP should be considered as an alternative to treat patients on chronic opioids for pain.
Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to Ultraviolet A light with the KXL II system according to the programmed treatment pattern.
This is an investigator-initiated efficacious, single-center, open-label clinical trial study. This study hypothesizes that the use of reduced PTV margins in oART for postoperative treatment of endometrial and cervical cancer could decrease toxicity and achieve more accurate dosimetric coverage. A dose of 45 or 50.4 Gy is delivered to clinical target volume (CTV) with reduced margin oART. Patients receive cisplatin based concurrent chemotherapy. The primary endpoint is acute toxicity. The first 10 patients were included in the study that have demonstrated the feasibility of reducing the margin (ClinicalTrials.gov ID: NCT05682950).
ETHNOPHARMACOLOGICAL RELEVANCE: Epimedium brevicornu Maxim. is a traditional medicinal Chinese herb that is enriched with flavonoids, which have remarkably high medicinal value. Icariin (ICA) is a marker compound isolated from the total flavonoids of Epimedium brevicornu Maxim. It has been shown to improve Neurodegenerative disease, therefore, ICA is probably a potential drug for treating AD.
MATERIALS AND METHODS: The 6-8-week-old SPF-class male ICR mice were randomly divided into 8 groups for modeling, and then the mice were administered orally with ICA for 21 days. The behavioral experiments were conducted to evaluate if learning and memory behavior were absent in mice, confirming that infusion of Amyloid β-protein (Aβ)1-42 caused significant memory impairment. The morphological changes and damage of neurons in the mice's brains were observed by HE and Nissl staining. The spinous protrusions (dendritic spines) on neuronal dendrites were investigated by Golgi-Cox staining. The molecular mechanism of ICA was examined by Western Blot. The protein docking of ICA and Donepezil with BDNF were analyzed to determine their interaction.
RESULTS: The behavioral experimental results showed that in Aβ1-42-induced AD mice, the learning and memory abilities were improved after using ICA. At the same time, the low, medium, and high doses of ICA could reduce the content of Aβ1-42 in the hippocampus of AD mice, repair neuronal damage, enhance synaptic plasticity, as well as increase the expression of BDNF, TrκB, CREB, Akt, GAP43, PSD95, and SYN proteins in the hippocampus of mice. However, the effect with high doses of ICA is more pronounced. The high-dose administration of ICA has the best therapeutic effect on AD mice. After administering the inhibitor k252a, the therapeutic effect of ICA was reversed. The macromolecular docking results of ICA and BDNF protein demonstrated a strong interaction of -7.8 kcal/mol, which indicates that ICA plays a therapeutic role in AD mice by regulating the BDNF-TrκB signaling pathway.
CONCLUSIONS: The results confirm that ICA can repair neuronal damage, enhance synaptic plasticity, as well as ultimately improve learning and memory impairment through the regulation of the BDNF-TrκB signaling pathway.
A method for performing boron neutron capture therapy for the treatment of tumors is disclosed. The method includes administering to a patient an iodinated sulfidohydroborane, a boron-10-containing compound. The site of the tumor is localized by visualizing the increased concentration of the iodine labelled compound at the tumor. The targeted tumor is then irradiated with a beam of neutrons having an energy distribution effective for neutron capture. Destruction of the tumor occurs due to high LET particle irradiation of the tissue secondary to the incident neutrons being captured by the boron-10 nuclei. Iodinated sulfidohydroboranes are disclosed which are especially suitable for the method of the invention. In a preferred embodiment, a compound having the formula Na 4  B 12  I 11  SSB 12  I 11 , or another pharmaceutically acceptable salt of the compound, may be administered to a cancer patient for boron neutron capture therapy.
The invention discloses a composition having a function of reducing activity of periodontal pathogens. The composition consists of a honeysuckle extract, a fructus momordicae extract, a green tea extract, lactobacillus paracasei and fructus phyllanthi powder. The preparation method comprises the following steps: preparing the honeysuckle extract, the fructus momordicae extract and the green tea extract in a separated mode, and preparing the fructus phyllanthi powder; and uniformly mixing the prepared honeysuckle extract, fructus momordicae extract, green tea extract and fructus phyllanthi powder with lactobacillus paracasei, so that the composition has the function of reducing the activity of the periodontal pathogens is obtained. The invention discloses application of the composition in preparing foods or health care foods and application of the composition in preparing daily chemical products for oral care. The composition disclosed by the invention can be prepared into various foods and oral care articles, so that the function of effectively reducing the activity of the periodontal pathogens is achieved when people eat the foots and accept oral care, and the teeth of the people are fully protected. The product disclosed by the invention, even being eaten for a long time or taken as tea, is free from adverse reactions and side effects.
Sarcopenia is a geriatric syndrome characterized by a functional decline in muscle. The prevalence of sarcopenia increases with natural aging, becoming a serious health problem among elderly individuals. Therefore, understanding the pathology of sarcopenia is critical for inhibiting age-related alterations and promoting health and longevity in elderly individuals. The development of sarcopenia may be influenced by interactions between visceral and subcutaneous adipose tissue and skeletal muscle, particularly under conditions of chronic low-grade inflammation and metabolic dysfunction. This hypothesis is supported by the following observations: (i) accumulation of senescent cells in both adipose tissue and skeletal muscle with age; (ii) gut dysbiosis, characterized by an imbalance in gut microbial communities as the main trigger for inflammation, sarcopenia, and aged adipose tissue; and (iii) microbial dysbiosis, which could impact the onset or progression of a senescent state. Moreover, adipose tissue acts as an endocrine organ, releasing molecules that participate in intricate communication networks between organs. Our discussion focuses on novel adipokines and their role in regulating adipose tissue and muscle, particularly those influenced by aging and obesity, emphasizing their contributions to disease development. On the basis of these findings, we propose that age-related adipose tissue and sarcopenia are disorders characterized by chronic inflammation and metabolic dysregulation. Finally, we explore new potential therapeutic strategies involving specialized proresolving mediator (SPM) G protein-coupled receptor (GPCR) agonists, non-SPM GPCR agonists, transient receptor potential (TRP) channels, antidiabetic drugs in conjunction with probiotics and prebiotics, and compounds designed to target senescent cells and mitigate their pro-inflammatory activity.
The group of patients were discharged before 14 days. GFR assessment at time of discharge and again at 1 year follow up.
PURPOSE:To deactivate type B hepatitis virus without causing loss of useful components, by irradiating blood with ultraviolet rays with specific intensity while circulating the blood through a treating chamber consisting of ultraviolet permeable glass. CONSTITUTION:Type B hepatitis virus is deactivated by irradiating blood ultraviolet rays which are transmitted through ultraviolet permeable glass and adjusted to 1,0004n5,000muw/cm<2> ultraviolet intensity in a treating chamber consisting of the ultraviolet permeable glass while circulating the blood in the treating chamber. Heat treatment or chemical treatment is carried out as a method for deactivating type B hepatitis virus, but it has the problem of denaturation of useful components such as albumin globulin, fibrinogen, etc. in blood (plasma). In the method of ultraviolet irradiation, HBs antigen value in blood is lowered in a short time, and destruction of the useful components is extremely a little. The irradiation time is usually 120min, and both HBs antigen value and HBe antigen value are extremely reduced.
Bronchiolitis obliterans (BO) was defined as the presence of signs and symptoms of chronic obstructive lung disease: A) previously documented acute lower respiratory infection (ALRI) with persistence of airway obstruction and respiratory signs and symptoms, such as: dyspnea, tachypnea, retractions, persistent cough, increased antero-posterior diameter of the chest, persistent wheezing, crackles, exercise intolerance; B) findings such as: hyperinflation, atelectasis, and mosaic oligohemia on CT scan; and C) persistent obstructive pattern on pulmonary function test.

Patients were randomly assigned by pharmacy staff in blocks of 4 to receive either capsules of azithromycin 250 mg (Group 1) or placebo (Group 2) 3 days a week for 6 months. Patients whose weight was less than 40 kg received 250 mg 3 days a week (Monday, Wednesday, and Friday) and those weighing more than 40 kg received 500 mg in the same scheme, according to randomization to active drug or placebo. Pulmonary function and number of exacerbations were evaluated. Spirometry and plethysmography were performed at baseline and at 6 months. Variables analyzed were Forced vital capacity (FVC),Flow expiratory volume at the first second (FEV1), Total lung capacity (TLC),Residual volumen(RV),especific conductance (sGaw). Patients had been clinically stable over the previous three weeks.
Participants enrolled in the home follow-up group will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. At enrollment, they will receive instruction for timing of contact, how to use the LSPT, as well as the test itself. The participant will take the pregnancy test at home in 14 days and answer completion questions by text message for follow-up. Patients that screen positive will be asked to return to clinic for a visit with a provider.
OBJECTIVE: To examine associations between prolonged early household food insecurity (FI) during pregnancy, infancy, and toddlerhood, and child feeding practices, and the mediating role of dysfunctional parent-child interactions.
METHODS: We conducted secondary longitudinal analyses of data from the Starting Early Program (StEP) randomized controlled trial, which studied a primary care-based child obesity prevention program for low-income Hispanic families. Our independent variable was FI, using the USDA Food Security Module, during the third trimester of pregnancy and at child ages 10- and 19-months. Frequency of reported FI was defined by the number of periods with FI (0, 1, 2, or 3). Our dependent variables were feeding practices at child age 28-months using the Comprehensive Feeding Practices Questionnaire. Our mediating variable was dysfunctional parent-child interactions using the Parenting Stress Index subscale at age 19-months. We used linear regression to determine associations between frequency of reported FI and feeding practices adjusting for covariates, and mediation analyses to determine if dysfunctional parent-child interactions mediate these associations.
RESULTS: Three hundred and forty four mothers completed assessments at child age 28-months. Of the 12 feeding practices examined, higher frequency of reported FI was positively associated with using food as a reward, restriction of food for weight control, and using food for emotional regulation, and was negatively associated with monitoring of less healthy foods. There was a significant indirect effect of frequency of reported FI on these practices through dysfunctional parent-child interactions.
CONCLUSION: Higher frequency of reported FI was associated with four feeding practices, through dysfunctional parent-child interactions. Understanding these pathways can inform preventive interventions.
The invention relates to a plaster for treating vaginal discharge diseases of women. The plaster is prepared from the following raw materials in parts by weight: 2-3 parts of sargentgloryvine stem, 1-2 parts of Cortex Fraxini, 2-3 parts of angelica, 1-2 parts of Herba Patriniae, 3-4 parts of houttuynia, 1-2 parts of glabrous greenbrier rhizome, 3-5 parts of ailanthus bark, 2-3 parts of angelica glabra and a proper amount of plaster substrate. The use method is as follows: grinding the sargentgloryvine stem and the Cortex Fraxini into fine powder, and filtering with a 800-mesh sieve for later use; decocting the angelica, the Herba Patriniae, the houttuynia, the glabrous greenbrier rhizome, the ailanthus bark and the angelica glabra in water, filtering, and condensing into extract; and uniformly mixing the fine powder and the extract, adding the plaster substrate and then stirring. The invention has exclusive prescription, the prepared plaster is pasted at the navel for specifically treating vaginal discharge diseases of women with obvious curative effect. Since the plaster is a traditional Chinese medicine preparation, the plaster has no side effects. The invention is only applicable to patients with vaginal discharge diseases, but not applicable to pregnant women with vaginal discharge diseases.
The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.
GLUCOTROL XL should be administered orally with breakfast or the first main meal of the day.

The recommended starting dose of GLUCOTROL XL is 5 mg once daily. Start patients at increased risk for hypoglycemia (e.g. the elderly or patients with hepatic insufficiency) at 2.5 mg [see Use in Specific Population (8.5, 8.6)].

Dosage adjustment can be made based on the patient's glycemic control. The maximum recommended dose is 20 mg once daily.

Patients receiving immediate release glipizide may be switched to GLUCOTROL XL once daily at the nearest equivalent total daily dose.
PROBLEM TO BE SOLVED: To provide a production of ocher granules which are prevented from disadvantageous scattering of ocher powder and can be used readily as a cosmetic composition, and to provide a cosmetic composition containing the ocher granules as a major component, and supplying nutrients to the skin and eliminating various kinds of contaminants which inhibit supply of nutrients to the skin and exhibiting an antibacterial effect and an effect of promoting blood circulation via far infrared rays.SOLUTION: The method for producing the ocher granules includes: a step of mixing 20.0-95.0 pts.wt. of ocher, 0.1-40.0 pts.wt. of an excipient, 0.1-3.0 pts.wt. of a disintegrating agent, and 0.001-25.0 pts.wt. of an additive; a step of adding 0.1-10.0 pts.wt. of a binder to the resultant mixture to aggregate the mixture to form grains; a step of drying the grains and performing granulation to form granules having a predetermined size, a step of adding and mixing 0.1 to 2.0 pts.wt. of a lubricant to the granulated granules; and a step of performing purification to form ocher granules having a diameter of 100 to 1,000 μm.
PROBLEM TO BE SOLVED: To obtain the subject new compound useful as a new analgesic having the activity to inhibit the binding of nociceptin to a nociceptin receptor ORL1, medicament for overcoming narcotic analgesic tolerance, medicament for overcoming narcotic analgesic dependency, analgesic action potentiator, or the like. SOLUTION: This new compound is a compound of formula I [Cy is a (substituted) 6-15C mono, bi or tricyclic aliphatic carbocyclic group; formula II denotes a (substituted) 3-9C monocyclic aliphatic nitrogen-contg. heterocyclic group; R1 is H, a (substituted) lower alkyl or the like; R2 is H or a lower alkyl; X is H, a halogen or the like], e.g. 8-cyclooctylmethyl-1-phenyl-1,3,8- triazaspiro[4.5]decan-4-one. The compound of formula I is obtained by reaction between a compound of formula III [formula IV denotes a (substituted) 3-9C monocyclic aliphatic nitrogen-contg. heterocyclic group; R1p is an amino- protective group, H or the like] and a compound of formula V [Cyp is a (substituted) 6-15C mono, bi or tricyclic aliphatic carbocyclic group; L1 is an eliminable group] followed by, as necessary, removing the protective group in the resultant compound.
BACKGROUND: Clinical trial scenarios can be modeled using data from observational studies, providing critical information for design of real-world trials. The Huntington's Disease Integrated Staging System (HD-ISS) characterizes disease progression over an individual's lifespan and allows for flexibility in the design of trials with the goal of delaying progression. Enrichment methods can be applied to the HD-ISS to identify subgroups requiring smaller estimated sample sizes.
OBJECTIVE: Investigate time to the event of functional decline (HD-ISS Stage 3) as an endpoint for trials in HD and present sample size estimates after enrichment.
METHODS: We classified individuals from observational studies according to the HD-ISS. We assessed the ability of the prognostic index normed (PIN) and its components to predict time to HD-ISS Stage 3. For enrichment, we formed groups from deciles of the baseline PIN distribution for HD-ISS Stage 2 participants. We selected enrichment subgroups closer to Stage 3 transition and estimated sample sizes, using delay in the transition time as the effect size.
RESULTS: In predicting time to HD-ISS Stage 3, PIN outperforms its components. Survival curves for each PIN decile show that groups with PIN from 1.48 to 2.74 have median time to Stage 3 of approximately 2 years and these are combined to create enrichment subgroups. Sample size estimates are presented by enrichment subgroup.
CONCLUSIONS: PIN is predictive of functional decline. A delay of 9 months or more in the transition to Stage 3 for an enriched sample yields feasible sample size estimates, demonstrating that this approach can aid in planning future trials. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.